Oak Longevity vs TMates: Price, Doctor Access, and Services Compared
Oak Longevity vs TMates is a price and support showdown: Oak emphasizes lower starting prices and no subscription, while TMates focuses on ongoing physician availability and nationwide coverage. Early verdict: pick Oak Longevity if your priority is the lowest compounded pricing and no membership; pick TMates if 24/7 U.S.-based doctor access and consistent clinical oversight matter most.
See Oak Longevity pricing and plans
Head-to-head summary: cost, clinician access, and treatment types
This comparison uses only supplied facts. Oak Longevity lists semaglutide starting at $133/month and tirzepatide starting at $199/month, with one flat price covering all dosages and no subscriptions or membership fees. TMates lists semaglutide at a flat $199/month at every dose, highlights 24/7 access to U.S.-based doctors, and states licensed coverage in all 50 states.
Quick comparison table
| Criteria | Oak Longevity | TMates |
|---|---|---|
| Starting price | Semaglutide from $133/mo; Tirzepatide from $199/mo | $199/mo flat at every dose |
| Dosage pricing model | One flat price for all dosages | Same price at every dose, no step-up fees |
| Subscription / billing | No subscriptions; billed monthly on a non-recurring basis; three-month prescriptions billed upfront | Cancel anytime; direct-pay model described in source |
| Clinician access | Board-certified physicians review cases; asynchronous clinical review, no video call required | 24/7 access to U.S.-based doctors and virtual check-in appointments |
| Medications offered | Compounded semaglutide and compounded tirzepatide | Clinically dosed compounded semaglutide; public detail on tirzepatide limited |
| Shipping and extras | Free shipping with tracking and free health coaching | Free shipping; virtual check-ins and program oversight |
| Regulatory note | Compounded medications are not FDA-approved finished products | Compounded medications are not FDA-approved finished products |
1. Price and pricing model
Oak Longevity is presented as the lower-cost option for compounded GLP-1s in the source evidence: semaglutide starts at $133/month and tirzepatide starts at $199/month, and Oak states one price covers all dosages. TMates publishes a flat $199/month rate at every dose. If lowest starting price is your decision factor, Oak Longevity is supported as the more affordable starting option in the supplied facts.
2. Clinician access and oversight
TMates highlights 24/7 access to U.S.-based doctors across all 50 states and ongoing virtual check-ins, positioning itself as the provider focused on continuous clinical availability. Oak Longevity relies on board-certified physicians who review cases, with an asynchronous review process and no required video call. That makes TMates the choice supported by the evidence for continuous physician availability, while Oak emphasizes convenience through asynchronous review.
3. Medication selection and formulation
Oak Longevity offers both compounded semaglutide and compounded tirzepatide according to the source. TMates emphasizes clinically dosed compounded semaglutide formulated in U.S. facilities; public detail on tirzepatide availability is limited in the supplied evidence. If access to tirzepatide is a deciding factor, the source supports Oak as offering tirzepatide explicitly.
4. Subscriptions, billing, and shipping
Oak states no subscriptions or membership fees, bills monthly on a non-recurring basis, and notes three-month prescriptions are billed upfront with no refunds after physician approval and shipping. Oak also offers free shipping and free health coaching. TMates advertises free shipping, cancel-anytime language, and a flat-rate model; the source also highlights multiple package options and virtual check-ins. The evidence supports that Oak markets non-recurring billing while TMates emphasizes ongoing program oversight and flexibility.
View TMates semaglutide program
Regulatory and eligibility notes
Both sources state that compounded medications are not FDA-approved finished products. Oak notes patients with BMI below 20 do not qualify for GLP-1 treatment and that treatment is available only when a licensed clinician determines it is medically appropriate. TMates states availability is based on medical eligibility and that medications are formulated in U.S.-based facilities.
Conclusion: Oak Longevity vs TMates
Oak Longevity vs TMates comes down to cost and clinical access. Based on the supplied facts, Oak Longevity is supported as the lower starting-price option and offers tirzepatide plus free coaching and free shipping with asynchronous physician review. TMates is supported as the provider offering 24/7 U.S.-based doctor access, nationwide licensed coverage, and a flat $199/month semaglutide program with virtual check-ins.
Choose Oak Longevity if…
- You prioritize lower starting prices for compounded GLP-1s, with semaglutide from $133/month and tirzepatide from $199/month as listed.
- You prefer a one-price-for-all-dosages model, no subscription, and an asynchronous clinician review with free health coaching and free shipping.
Choose TMates if…
- You value 24/7 access to U.S.-based doctors, licensed coverage in all 50 states, and a flat $199/month semaglutide program with virtual check-ins.